-
CDK Related Products (487)
Related Products (487)
-
CDK2-IN-25
0 ImagesCat. No.: HY-161291CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC50 of 0.149 μM.
-
CDK9-IN-39
0 ImagesCat. No.: HY-176484CDK9-IN-39 (1-7a-B1) is an orally active cyclin-dependent kinase 9 (CDK9) inhibitor with an IC50 of 6.51 nM. CDK9-IN-39 induces cell apoptosis by inhibiting the phosphorylation of RNA polymerase II at Ser2 and can be used for study of colorectal cancer .
-
CDK1/CycA1 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70651CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK1.
-
PI3K/AKT-IN-4
0 ImagesCat. No.: HY-162802PI3K/AKT-IN-4 (compound 3) is a diterpenoid that can be isolated from the roots and rhizomes of Salvia castanea Dielsf. PI3K/AKT-IN-4 has antitumor activity, inhibiting cell viability and proliferation (IC50=4.72 μM) and promoting apoptosis by blocking the G0/G1 phase of the Hep3B cell cycle, inducing mitochondrial dysfunction and oxidative stress. In addition, PI3K/AKT-IN-4 inhibits hepatocellular carcinoma by inhibiting the PI3K-Akt signaling pathway and binding to PARP1 and CDK2 targets.
-
CDK7-IN-13
0 ImagesCat. No.: HY-147597CAS No.: 2765676-20-6
-
XC219
0 ImagesCat. No.: HY-162785XC219 (compound 43) is a cyclin-dependent kinase CDK) inhibitor, that covalently binds to CDK active site Lys. XC219 can be used in antifungal research.
-
(Rac)-Roscovitine
0 ImagesCat. No.: HY-50892CAS No.: 186692-44-4Synonyms: (Rac)-Seliciclib; (Rac)-CYC202(Rac)-Roscovitine ((Rac)-Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac)-Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac)-Roscovitine induces apoptosis in cancer cells. (Rac)-Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation.
-
CDK5/p25NCK Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70684CDK5 can be mapped to chromosome 7q36 and its expression is upregulated by the transcription factors Fos and CREB through the MEK/ERK pathway and by δFosB. CDK5 plays a vital role in the central nervous system but has functions in other cell types. CDK5 has recently been implicated in diseases, including the development and progression of cancer and neurodegenerative diseases. CDK5/p25NCK Recombinant Human Active Protein Kinase is an ortholog of CDK5.
-
CDK9-IN-47
0 ImagesCat. No.: HY-182069CDK9-IN-47 is an orally active and selective CDK9 inhibitor with an IC50 of 1.4 nM. CDK9-IN-47 inhibits tumor cell proliferation, migration and invasion, and induces apoptosis. CDK9-IN-47 can be used for the research of triple-negative breast cancer.
-
CDK2/CycO Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70674CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK2.
-
CDK16/CycY Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70664CDK16/CycY Recombinant Human Active Protein Kinase is a PCTAIRE kinase and its activity is dependent on the Cyclin Y (CCNY) family. CCNY is an oncoprotein in various cancers.
-
NL13
0 ImagesCat. No.: HY-162895NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth.
-
CDK12/13-IN-1
0 ImagesCat. No.: HY-160284CAS No.: 2407774-31-4CDK12/13-IN-1 (Compound 4) is a CDK12/13 inhibitor. CDK12/13-IN-1 has antitumor activity .
